Cytokine therapy or structured treatment interruptions in HIV infection: which is best?

Bibliography

• AUTRAN B, CARCELIN G, LI TS et al: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 277:112–116.
   PubMed Web of Science ®Google Scholar
• ••The effect of HAART on immunefunction.
   Google Scholar
• PALELLA FJ JR DELANEY KM, MOORMAN AC et al.: Declining morbidity among patients with advanced human immunodeficiency virus. HIV Out-patient Study Investigators. N Engl. J. Med. (1998) 338(13):853–860.
   PubMedGoogle Scholar
• PERELSON AS, NEUMANN AU, MARKOWITZ M, LEONARD JM, HO DD: HIV-1 dynamics in vivo virion clearance rate, infected cell lifespan and viral generation time. Science (1996) 271(5255):1582–1586.
   PubMed Web of Science ®Google Scholar
• FINZI D, BLANKSON J, SILICIANO JD et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistance of HIV-1, even in patients on effective combination therapy. Nat. Med. (1999) 5(5):512–517.
   PubMed Web of Science ®Google Scholar
• •Continuous HAART cannot eradicate HIV.
   Google Scholar
• CARR A, SAMARAS K, CHISHOLM DJ, COOPER DA et al: Pathogenesis of HIV-1 protease-associated peripheral lipodystro-phy, hyperlipidaemia and insulin resistance. Lancet (1998) 351(9119):1881–1883.
   PubMed Web of Science ®Google Scholar
• DURAN S, SAVES M, SPIRE B et al: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS (2001) 15: 2441–2444.
   PubMed Web of Science ®Google Scholar
• LEDERBERGER B, EGGER M, OPRAVIL M et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet (1999) 353:863–868.
   PubMed Web of Science ®Google Scholar
• ROOK AH, MASUR H, LANE HC et al: Interleukine-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. Clin. Invest. (1983) 72(1):398–403.
   Google Scholar
• HEFENEIDER SH, CONLON PJ, HENNEY CS AND GILLIS S: In vivo interleukine-2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. Immune]. (1983) 130(1):222–227.
   PubMed Web of Science ®Google Scholar
• SMITH KA: Interleukine-2: inception, impact and implications. Science (1988) 240(4856):1169–1176.
   PubMed Web of Science ®Google Scholar
• ••First characterisation of IL-2.
   Google Scholar
• HARTSHORN KL, NEUMEYER D, VOGT MW, SCHOOLEY RT, HIRSCH MS: Activity of interferons alpha, beta and gamma against human immunodeficiency virus replication in vitro. AIDS Res. Hum. Removiruses (1987) 3:125–133.
   PubMed Web of Science ®Google Scholar
• GENDELMAN HE, BACA LM, TURPIN J et al.: Regulation of HIV replication in infected monocytes by interferon-alpha. Mechanisms for viral restriction. Immune]. (1990) 145:2669–2676.
   Google Scholar
• LISZIEWICZ J, ROSENBERG E, LIEBERMAN J et al.: Control of HIV despite the discontinuation of antiretroviral therapy. N EngL J. Med. (1999) 340:1683–1684.
   PubMed Web of Science ®Google Scholar
• KOVACS JA, VOGEL S, ALBERT JM et al.: Controlled trial of interleukine-2 infusions in patients infected with the human immunodeficiency virus. N Engl. J. Med. (1996) 335:1350–1356.
   PubMed Web of Science ®Google Scholar
• ••First randomised trial of IL-2 therapy inHIV patients.
   Google Scholar
• KOVACS JA, BASELER M, DEWAR RJ et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with immunodeficiency virus infection. A preliminary study. N Engl. J. Med. (1995) 332(9):567–575.
   PubMed Web of Science ®Google Scholar
• DAVEY RT JR CHAITT DG, ALBERT JM et al: A randomized trial of high- versus low-dose subcutaneous interleukin-2 out-patient therapy for early human immunodeficiency virus type-1 infection. .1. Infect. Dis. (1999) 179:849–858.
   Google Scholar
• ABRAMS DI, BEBCHUK JD, DENNING ET, MARKOWITZ NP: IL-2 therapy produces no change in HIV RNA after one year. Beirn Community Programs for Clinical Research on AIDS. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (17–20 September 2000). Abstract L–11.
   Google Scholar
• ARNO A, RUIZ L, JUAN M et al: Efficacyof low dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus Type 1 in persons with 250/microL CD4 T cells and undetectable plasma viral load. Infect. Dis. (1999) 180:56–60.
   Google Scholar
• CARR A, EMERY S, LOYD A et al.: Out-patient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. J. Infect. Dis. (1998) 178:992–999.
   PubMed Web of Science ®Google Scholar
• DAVEY RT JR, MURPHY RL, GRAZIANO FM et al.: Immunologic and virologic effects of subcutaneous inter-leukin-2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA (2000) 284:183–189.
   PubMedGoogle Scholar
• HENGGE UR, GOOS M, ESSER S et al: Randomized, controlled Phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS (1998) 12:F225–F234.
   Google Scholar
• LEVY Y, CAPITANT C, HOUHOU S et al.: Comparison of subcutaneous and intravenous interleukine-2 in asymptomatic HIV-1 infection: a randomized controlled trial. ANRS 048 study group. Lancet (1999) 353:1923–1929.
   Google Scholar
• •Effects of IL-2 on recall antigens.
   Google Scholar
• LEVY Y, CAPITANT C, LASCAUX AS et al.: Effect of subcutaneous (SC) IL-2 therapy combined with HAART in HIV-infected patients. Results of the ANRS 079 randomized trial. 8th Conference on Retro viruses and Opportunistic Infections. Chicago, Illinois, USA (4–8 February 2001). Abstract 344.
   Google Scholar
• LOSSO MH, BELLOSO WH, EMERY S et al.: A randomized, controlled Phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretroviral versus antiretroviral alone in human immunodeficiency-virus infected patients with 350/mm3. I. Infect. Dis. (2000) 181:1614–1621.
   PubMed Web of Science ®Google Scholar
• MITZUYASU R: Prospective, randomized, controlled Phase II study of highly active antiretroviral therapy (HAART) with continuous IV (CIV) or subcutaneous (SC) interleukin-2 (IL-2) in HIV-infected patients with CD4+ counts of 50–350 cells/ mm3: ACTG-328 - final results at 84 weeks. 8th Conference on Removiruses and Opportunistic Infections. Chicago, Illinois, USA (4–8 February 2001). Abstract 17.
   Google Scholar
• SARAVOLATZ L, MITZUYASU R, SNELLER M et al.: Duration of proleukin IL-2 therapy is more important than total dose in achieving CD4 expension. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, Louisiana, USA (September 1996). Abstract I–149.
   Google Scholar
• DURIER C, EMILIE D, ESTAQUIERJ et al.: Effects of subcutaneous (SC) IL-2 combined with HAART on immunological restoration in HIV-infected patients. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, USA (4–8 February 2001). Abstract 345.
   Google Scholar
• ORHOLM M, PEDERSEN C, MATHIESEN L, DOWD P, NIELSEN JO: Suppression of the p24 antigen in serum from HIV-infected individuals with low dose alpha-interferon and zidovudine: a pilot study. AIDS (1989) 3(2):97–100.
   PubMedGoogle Scholar
• FERNANDEZ-CRUZ E, LANG JM, FRISSEN J et al.: Zidovudine plus interferon alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts 150x10 (6)/L: results of the Zidon trial. Zidon study group. AIDS (1995) 9(9):1025–1035.
   Google Scholar
• LANDAU A, BATISSE D, PIKETTY C AND KAZATCHKINE MD: Effect of interferon and ribavirin on HIV viral load. AIDS (2000) 14(1):96–97.
   PubMedGoogle Scholar
• FRISSEN PH, VAN DER ENDE ME, TEN NAPEL CH et al: Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus Type 1 infection.' Infect. Dis. (1994) 169(6):1351–1355.
   Google Scholar
• ••First report of a randomised trial of theantiviral efficacy of LEN-a.
   Google Scholar
• REYNES J, ROUZIER-PANIS R, LAUGHLIN M, BAILLAT V, KANOUNI T, GARAUD JJ: Antiretroviral activity and tolerability of PEG-Interferon-a-2b in patients on stable background therapy: results of phase I/II study. 7th Conference on Retro viruses and Opportunistic Infections. San Francisco, California, USA (30 January-2 February 2000). Abstract 542.
   Google Scholar
• •Antiviral efficacy of PEG-IFN.
   Google Scholar
• RODRIGUEZ A, MOLINA J, SANDS M et al: Virologic and immunologic impact of pegylated interferon alpha 2B in HIV-infected patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, Illinois, USA (19–22 December 2001). Abstract 1–1938.
   Google Scholar
• ••Antiviral efficacy of PEG-IFN in arandomised controlled trial.
   Google Scholar
• EMILIE D, BURGARD M, LASCOUX-COMBE C et al: Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha results from Primoferon A (ANRS 086) Study. AIDS (2001) 15(11):1435–1437.
   PubMed Web of Science ®Google Scholar
• ROSENBERG ES, ALTFELD M, POON SH et al.: Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 407:523–526.
   PubMed Web of Science ®Google Scholar
• HOEN B, BURARD M, FOURNIER let al.: Structured treatment interruptions (STI) in acute seroconverters: interim results of the multicenter prospective PRIMSTOP pilot trial (ANRS 100). 9th Conference on Retro viruses and Opportunistic Infections. Seattle, Washington, USA (24–28 February 2002). Abstract 530.
   Google Scholar
• YU X, ADDO MM, FITZPATRICK C et al.: Sequential broadening of HIV-1 specific CTL responses during supervised treatment interruption in treated acute infection. 9th Conference on Retro viruses and Opportunistic Infections. Seattle, Washington, USA (24–28 February 2002). Abstract 537.
   Google Scholar
• MIRO J, PLANA M, ORTIZ GM et a/.: Structured treatment interruptions (STI) in patients receiving HAART since primary HIV-1 infection (PHI): spontaneous control of viremia in about one third of cases after 3 cycles off therapy. 9th Conference on Retro viruses and Opportunistic Infections. Seattle, Washington, USA (24–28 February 2002). Abstract 529.
   Google Scholar
• FAGARD C, LEBRAZ M, GUNTHARD H et al.: SSITT: a prospective trial of strategic treatment interruption in 128 patients. 8th Conference on Retro viruses and Opportunistic Infections. Chicago, Illinois, USA (4–8 February 2001). Abstract 357.
   Google Scholar
• RUIZ L, MARTINEZ-PICADO J, ROMEU J et al.: Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS(2000) .14:397–403.
   PubMed Web of Science ®Google Scholar
• RUIZ L, CARCELAIN G, MARTINEZ-PICADO J et al.: HIV dynamics and T cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS(2001) 15:F19–F27.
   PubMed Web of Science ®Google Scholar
• GARCIA F, MONTSERRAT P, ORTIZ GM et al.: The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS (2001) 15:F29–F40.
   Google Scholar
• ORTIZ GM, WELLONS M, BRAN-CATO J et al.: Structured antiretroviral treatment interruptions in chronically HIV-1 infected subjects. Proc. Natl. Acad. Sci. USA (2001) 98(23):13288–13293.
   PubMedGoogle Scholar
• •Evaluation of side effects in STI in CHI.
   Google Scholar
• HIRSCHEL B, FAGARD C, OXENIUS A, GUNTHARD H, GARCIA F for the Swiss HIV Cohort Study: SSITT: a prospective trial of treatment interruptions in HIV infection. 9th Conference on Retro viruses and Opportunistic Infections. Seattle, Washington, USA (24–28 February 2002). Abstract 528.
   Google Scholar
• BONHOEFFER S, REMBISZEWSKI M, ORTIZ GM, NIXON DF: Risks and benefits of structured antiretroviral drug therapy interruption in HIV-1 infection. AIDS (2000) 14:2313–22.
   PubMed Web of Science ®Google Scholar
• DORMAN KS, KAPLAN AH, LANGE K, SINSHEIMER JS: Mutation takes no vacation: can structured interruptions increase the risk of drug-resistant HIV-1? AIDS (2000) 25:398–402.
   Google Scholar
• MARTINEZ-PICADO J, MORALES-LOPETEGI K, WRIN T et al: Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS (2002) 16:895–899.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of STI-induced M184Vresistance.
   Google Scholar
• DYBUL M, CHUN TW, YODER C et al: Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic and toxicity parameters. Proc. Natl. Acad. Sci. USA (2001) 98:15161–15166.
   PubMed Web of Science ®Google Scholar
• •First results of short-cycle HAART.
   Google Scholar
• PERRIN L, TELENTI A: HIV treatment failure: testing for HIV resistance in clinical practice. Science (1998) 280:1871–1873.
   PubMed Web of Science ®Google Scholar
• PICKETTY C, CASTIEL P, BELEC L et al.: Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS (1998) 12:745–745.
   PubMedGoogle Scholar
• BARREIRO PM, DONA MC, CASTILLA J, SORIANO J: Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. AIDS (1999) 13:525–526.
   PubMed Web of Science ®Google Scholar
• DAVID D, NATT-IGHIL L, DUPONT B, MARAL J, GACHOT B: Rapid effect of interleulkin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. I Infect. Dis. (2001) 183:730–735.
   PubMedGoogle Scholar
• ••Effect of IL-2 in patients with CD4+200 cells/mm3.
   Google Scholar